Chastre J, Trouillet J L, Vuagnat A, Joly-Guillou M L, Clavier H, Dombret M C, Gibert C
Service de Réanimation Médicale, Hôpital Bichat, Paris, France.
Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1165-72. doi: 10.1164/ajrccm.157.4.9708057.
To describe the epidemiologic and microbial aspects of ventilator-associated pneumonia (VAP) in patients with acute respiratory distress syndrome (ARDS), we prospectively evaluated 243 consecutive patients who required mechanical ventilation (MV) for > or = 48 h, 56 of whom developed ARDS as defined by a Murray lung injury score > 2.5. We did this with bronchoscopic techniques when VAP was clinically suspected, before any modification of existing antimicrobial therapy. For all patients, the diagnosis of pneumonia was established on the basis of culture results of protected-specimen brush (PSB) (> or = 10(3) cfu/ml) and bronchoalvelolar lavage fluid (BALF) (> or = 10(4) cfu/ml) specimens, and direct examination of cells recovered by bronchoalveolar lavage (BAL) (< or = 5% of infected cells). Thirty-one (55%) of the 56 patients with ARDS developed VAP for a total of 41 episodes, as compared with only 53 (28%) of the 187 patients without ARDS for a total of 65 episodes (p = 0.0005). Only 10% of first episodes of VAP in patients with ARDS occurred before Day 7 of MV, as compared with 40% of the episodes in patients without ARDS (p = 0.005). All but two patients with ARDS who developed VAP had received antimicrobial treatment (mostly with broad-spectrum antibiotics) before the onset of infection, as compared with only 35 patients without ARDS (p = 0.004). The organisms most frequently isolated from patients with ARDS and VAP were methicillin-resistant Staphylococcus aureus (23%), nonfermenting gram-negative bacilli (21%), and Enterobacteriaceae (21%). These findings confirm that microbiologically provable VAP occurs far more often in patients with ARDS than in other ventilated patients. Because these patients are often treated with antibiotics early in the course of the syndrome, the onset of VAP is frequently delayed after the first week of MV, and is then caused mainly by methicillin-resistant S. aureus and other multiresistant microorganisms.
为描述急性呼吸窘迫综合征(ARDS)患者呼吸机相关性肺炎(VAP)的流行病学和微生物学特征,我们前瞻性评估了243例连续接受机械通气(MV)≥48小时的患者,其中56例根据Murray肺损伤评分>2.5被诊断为ARDS。当临床怀疑VAP时,在未改变现有抗菌治疗方案的情况下,我们采用支气管镜技术进行评估。对于所有患者,根据保护性标本刷检(PSB)(≥10³cfu/ml)和支气管肺泡灌洗(BALF)(≥10⁴cfu/ml)标本的培养结果以及支气管肺泡灌洗(BAL)回收细胞的直接检查(感染细胞≤5%)来确立肺炎诊断。56例ARDS患者中有31例(55%)发生VAP,共41次发作,而187例非ARDS患者中只有53例(28%)发生VAP,共65次发作(p = 0.0005)。ARDS患者VAP的首次发作仅有10%发生在MV第7天之前,而非ARDS患者为40%(p = 0.005)。发生VAP的ARDS患者中,除2例之外,其余患者在感染发作前均接受过抗菌治疗(大多使用广谱抗生素),而非ARDS患者只有35例(p = 0.004)。从ARDS合并VAP患者中最常分离出的病原体是耐甲氧西林金黄色葡萄球菌(23%)、非发酵革兰阴性杆菌(21%)和肠杆菌科细菌(21%)。这些发现证实,微生物学可证实的VAP在ARDS患者中比在其他接受机械通气的患者中更为常见。由于这些患者在综合征病程早期常接受抗生素治疗,VAP的发作常在MV第一周后延迟,且主要由耐甲氧西林金黄色葡萄球菌和其他多重耐药微生物引起。